Guangzhou Baiyunshan Pharmaceutical (SHA:600332, HKG:0874) branch entity, Baiyunshan Pharmaceutical General Factory, received drug registration from China's medical products regulator for oseltamivir phosphate for oral suspension.
The drug treats influenza A and B, according to a Tuesday filing with the Shanghai bourse.